EMA Authorised: Alprolix (eftrenonacog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

The EMA authorised Alprolix (eftrenonacog alfa) from Swedish Orphan Biovitrum AB (publ) for Hemophilia B. It is designated as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Alprolix (eftrenonacog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 30/04/2025. Orphan medicine